{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"data_sharing_plan":["IPD Sharing (as of January 2023): No"],"disease":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/91227"],"study_start_month":["1"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases","description":"Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients. Those with KRAS/NRAS/BRAF mutated tumors or cycle of conversion therapy ≤ 4 can benefit more from chemotharapy plus targeted therapyrather than from chemotharapy alone, with a tolerable toxicity profile.","dates":{"creation":"2013-01-15"},"accession":"91227","cross_references":{"ClinicalTrials___gov":["NCT06027775"]}}